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Abstract 
The current situation in Taiwan is not optimistic regarding the Department of Public Health 
expenses. The gratuitousness of the system promotes an abusive consumption by the population. 
The aims of this study are: to find the connection between common diseases, such as rheumatoid 
arthritis and diabetes, pulmonary diseases, such as pulmonary tuberculosis, and lung cancer and 
its most common metastatic cancers and to make an estimate of the total costs of the medical 
treatment based on data from the database, depending on the disease treated to help make 
predictions.  
To do so, the first step was gathering the data from the National Health Insurance Database 
(NHIDB), where patient’s medical data is recorded and diseases are encoded following the ICD9 
codes. The initial and final dates of the disease were also obtained (first and last visit with the 
same ICD9 code), as well as the age, sex and other useful data. Thereafter, transition times were 
calculated. Owing to the high number of data missing (especially patient’s death status) some 
hypotheses were necessary to be assumed and affected the transition time calculations. Due to 
the lack of data for some diseases, three of the initial proposal were eliminated and the final 
sample of population was of 417 patients with a total of 773 transitions in the model.  
Once the data was gathered, the semi-Markov model was built. It contained 9 states including 
health and death and all the possible connections between them. Using the semi-Markov package 
of the R studio program and the transition times calculated from the NHIDB, time dependent 
transition probabilities were obtained.  
At the same time, a model tree was built on the TreeAge program in order to simulate using the 
transition probabilities. A transient and a steady states simulation were run. The results were not 
as expected for the long term simulation due to an alteration of the Markov process. Regarding 
the short term simulation, mean time and cost results were obtained and analyzed.  
To conclude, based on the results obtained, this model can be used to simulate and predict 
virtual patients for short term simulations (one year). Long term simulation cannot be run 
using time dependent transition probabilities in such a big model (nine states) because 
simulated patients tend to remain in the model.  
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CHAPTER 1: INTRODUCTION 
1.1. Matter of study 
Worldwide, over one million people die of lung cancer each year. In the US, lung cancer is 
the most common cause of cancer deaths in both sexes, and mortality rates in women have risen 
500% since 1950.  
Between 1971 and 2001, age-standardized lung cancer mortality rates per 100,000 per year in 
Taiwan have increased sharply, from 12.66 to 32.93 among men and from 7.83 to 14.94 among 
women. In 2012, a total of 153,823 deaths were reported in Taiwan. The standardized mortality 
rate was 450.6 deaths per 100,000 population, which was 2.5% lower than the 2011 rate and 
19.3% lower than the 2001 rate. Today, in Taiwan, lung cancer is the leading cause of cancer 
death in women and the second leading cause in men. 
Epidemiological studies have shown that cigarette smoking is the major cause of lung cancer in 
both sexes. However, smoking habits do not seem to be the main explanation of the 
epidemiological characteristics of female lung cancer mortality in Asian countries, where the 
prevalence of smoking is relatively low but lung cancer mortality rates are relatively high. 
Factors other than smoking habits might contribute to the variability in lung cancer mortality. 
According to Taiwan’s Ministry of the Interior’s preliminary statistics, the 10 leading causes of 
death are shown in the following table sorted from highest to lowest impact on the Taiwanese 
population (Table 1). Furthermore, we can see the median age for each of the causes. 
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When it comes to malignant neoplasms, lung and liver cancer were still the two leading causes of 
cancer death in 2012 (Table 2). The number of deaths caused by cancer  was 43,665, accounting 
for 28.4% of total deaths, giving a 131.3 deaths per 100,000 standard population, which was 
0.7% lower than the rate of 2011 and 8.2% lower than the rate of 2001. Below is detailed the 
mortality rates in number of deaths out of 100,000 population depending on the type of cancer. 
2
 
                                                 
1
Source: www.mohw.gov.tw/en/Ministry/DisplayStatisticFile.aspx%3Fd%3D45244%26s%3D1+&cd=1&hl=es&ct=clnk&gl=es 
2
Source: www.mohw.gov.tw/en/Ministry/DisplayStatisticFile.aspx%3Fd%3D45244%26s%3D1+&cd=1&hl=es&ct=clnk&gl=es 
 
Unit: Rate per 100,000 population, % 
Both 
sexes 
Males Females 
Both 
sexes 
Males Females 
Both 
sexes 
Males Females 
 Malignant neoplasms 131.3 170.4 95.1 143.1 180.7 104.2 -8.2 -5.7 -8.7 
Cancers of trachea, bronchus and lung 25.4 34.7 17.0 28.3 38.6 17.5 -10.4 -10.2 -3.0 
Cancers of liver and intrahepatic bile ducts 24.7 35.8 14.4 28.0 40.9 14.9 -11.6 -12.4 -3.7 
Cancers of colon, rectum and anus 14.9 18.1 12.1 15.0 17.2 12.7 -0.4 5.2 -4.9 
Cancer of breast (Female) 11.6 … 11.6 10.7 … 10.7 8.1 … 8.1 
Cancer of oral cavity 8.1 15.3 1.2 6.7 12.2 1.1 20.7 25.1 10.3 
Cancer of stomach 6.9 9.0 5.0 10.5 13.9 7.0 -34.7 -35.5 -29.2 
Cancer of prostate 6.7 6.7 … 5.9 5.9 … 13.1 13.1 … 
Cancer of pancreas 4.9 5.8 4.0 4.3 5.4 3.2 13.0 8.6 24.1 
Cancer of esophagus 4.9 9.4 0.6 4.4 7.9 0.7 11.6 18.5 -18.2 
Cancers of cervix uteri and uterus, part unspecified 3.9 … 3.9 8.2 … 8.2 -52.6 … -52.6 
Table 2. Standardized mortality rates for leading causes of death 
2012 (A) 2001 (B) Percentage Change 
Both 
sexes 
Males Females 
Both 
sexes 
Males Females 
Both 
sexes 
Males Females 
All causes of death 75.0 73.0 78.0 71.0 70.0 74.0 4.0 3.0 4.0 
Malignant neoplasms 70.0 69.0 70.0 68.0 68.0 68.0 2.0 1.0 2.0 
Diseases of heart (except hypertensive diseases) 79.0 76.0 82.0 75.0 73.0 79.0 4.0 3.0 3.0 
Cerebrovascular diseases 79.0 76.0 81.0 75.0 73.0 77.0 4.0 3.0 4.0 
Pneumonia 83.0 82.0 85.0 79.0 78.0 82.0 4.0 4.0 3.0 
Diabetes mellitus 77.0 74.0 79.0 72.0 71.0 74.0 5.0 3.0 5.0 
Accidents and adverse effects 57.0 54.0 65.0 46.0 45.0 53.0 11.0 9.0 12.0 
Chronic lower respiratory diseases 83.0 83.0 84.0 79.0 78.0 80.0 4.0 5.0 4.0 
Hypertensive diseases 82.0 80.0 83.0 77.0 75.0 80.0 5.0 5.0 3.0 
Chronic liver disease and cirrhosis 58.0 54.0 73.0 58.0 53.0 69.0 - 1.0 4.0 
Nephritis, nephrotic syndrome and nephrosis 78.0 77.0 79.0 75.0 74.0 75.0 3.0 3.0 4.0 
Table 1. Median age at death for leading causes of death 
Unit：years 
2012 (A) 2001 (B) Change (A-B) 
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Hence, cancer –and especially lung cancer– is a serious and real problem that need to be solved 
as soon as possible and the aim of this thesis is to contribute to do so. Namely, it will look for 
relationships between illnesses that could possibly lead to lung cancer and trying to fathom the 
possible causes. Besides that, this thesis will study the relationship between lung cancer and the 
most common metastasis on Taiwanese population.  
1.2. Objectives 
The aims of the study were to observe the former relationship between major diseases in the 
Taiwanese by gathering the patient’s medical data from National Health Insurance research 
database (NHIRD) in Taiwan, to build and simulate a semi-Markov model which represents the 
disease evolution and to study the associated costs of treating the patients of each disease matter 
of study.  
1.3. Cost study 
Nowadays in Taiwan, the situation is not optimistic regarding the Department of Public 
Health. The government cannot afford the high budget intended for public health. One possible 
reason might be the abusive use by the population due to its gratuitousness. Another possible 
reason is the low doctor-to-population ratio, resulting in too many patients depending on too few 
doctors. Patients visit the doctor more frequently causing doctors to keep visits short to about 2 
to 5 minutes per patient. The aim of the cost study is making an estimate of the total costs of the 
medical treatment based on data from the database, depending on the disease treated to help 
make predictions.  
1.4. Background information 
The following sections contain a basic introduction about the most remarkable diseases 
studied in this thesis, as well as some statistics about the Taiwanese population diseased by them.   
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1.4.1. Pulmonary tuberculosis 
Pulmonary tuberculosis (TBC) is an infectious disease caused by bacteria that that attack 
your lungs. It is a potentially deadly disease, but it is curable if you get medical help right away 
and follow your doctor’s instructions. 
The bacterium (germ) that causes TB is called Mycobacterium tuberculosis and Mycobacterium 
bovis. This germ can cause other kinds of TB, but pulmonary TB is the most common. You can 
get sick with TB if you inhale the droplets exhaled by a person who has the disease. As an 
infection disease, immunosuppressive agents can cause the infection (drugs, alcohol and tobacco 
abusing, as well as AIDS, diabetes and other diseases and treatments lower the immunologic 
system). 
 Although TB is preventable and treatable, according to the World Health Organization, which in 
1993 declared tuberculosis a global emergency, up to 66 percent of the people who get sick with 
TB will die if they do not get proper medical care. 
Tuberculosis continues to be a major health problem worldwide. In 2008, the World Health 
Organization (WHO) estimated that one-third of the global population was infected with TB 
bacteria and in 2013, an estimated 9.0 million people developed TB and 1.5 million died from 
the disease, 360 000 of whom were HIV-positive. 
In 2011, there were 12,634 tuberculosis cases (54.5 cases per 100,000 population) and 638 
tuberculosis-related deaths (2.8 cases per 100,000 population) in Taiwan. The incidence rate fell 
1.7% as compared to 2010. Overall, the incidence rate has been showing a continuous downward 
trend. In the follow-up of treated cases, the treatment success rate in 2010 is 66.4%, lower than 
the WHO’s treatment success rate target of 85%. This suggests that more efforts need to be put 
into the control of tuberculosis. 
1.4.2. Primary lung cancer 
Primary lung cancer (carcinoma of the lung or pulmonary carcinoma) is a malignant lung 
tumor characterized by uncontrolled cell growth in tissues of the lung. It can spread beyond the 
lung by process of metastasis into nearby tissue or other parts of the body. The main primary 
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types are small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC). The 
most common symptoms are coughing (including coughing up blood), weight loss, shortness of 
breath, and chest pains.  
The majority of cases of lung cancer (80–90%) are due to long-term exposure to tobacco smoke. 
About 10–15% of cases occur in people who have never smoked. These cases are often caused 
by a combination of genetic factors and exposure to radon gas, asbestos or other forms of air 
pollution.  Lung cancer is seen by chest radiographs and computed tomography scans.  
Treatment and long-term outcomes depend on the type of cancer, the stage (degree of spread), 
and the person's overall health, measured by performance status. Common treatments 
include surgery, chemotherapy, and radiotherapy. NSCLC is sometimes treated with surgery, 
whereas SCLC usually responds better to chemotherapy and radiotherapy.  
As shown on table 2, lung cancer is the one which contributes the most on the number of annual 
deaths. When combining this fact with the long history of lung diseases in the Taiwanese 
population, it seems worth studying lung cancer and other lung diseases’ connections.  
Table 3: One, Five and Ten-Year Net Survival (%), Adult lung cancer patients aged 15-99, 
England & Wales on 2010-11 
    1-Year Survival (%) 5-Year Survival (%) 10-Year Survival (%) 
Men 
Net Survival 30.4 8.4 4 
95% LCL 30.1 7.5 2.8 
95% UCL 30.7 9.3 5.5 
Women 
Net Survival 35.1 11.6 6.5 
95% LCL 34.8 10.5 4.9 
95% UCL 35.3 12.6 8.4 
Adults 
Net Survival 32.1 9.5 4.9 
95% LCL 31.9 8.8 3.9 
95% UCL 32.3 10.2 6.1 
3
 
Here is an example of the high deadly rate of lung cancer. The probability of healing even drops 
when treating lung cancer that eventually passes to metastatic stage.  
                                                 
3
Source: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/lung/survival/lung-cancer-survival-statistics#one 
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1.4.3. Cancer metastasis 
The study includes cancer metastasis original from primary lung cancer. The most common 
places where metastatic cancers– coming from the lung develop are: 
 Adrenal glands metastatic cancer 
 Brain metastatic cancer 
 Bone metastatic cancer 
 Liver metastatic cancer 
Nonetheless, data for the patients suffering from a metastatic cancer original from lung primary 
cancer are scarce, due to the high deadly rate of primary lung cancer.  
1.4.4. NHIDB 
The data used in the project is taken from the National Health Insurance Data Bank 
(NHIDB). The NHIDB is a NHI database that collects all the Taiwanese medical visits between 
1997 and 2010. It uses the ICD9 code to encode the different diseases. Patient’s visits are 
separated in Inpatient visits and Outpatient visits. Inpatient visits have information about 
hospitalizations that lasted more than one day and outpatient visits regard one day visits.  
Both databases information is stored in columns. The information is really detailed and there are 
lots of specific data of every visit. Disease code, ID number, Date of birth, Physician name, visit 
date, medical department, diagnostic procedure, drug and treatment cost, treatment procedure 
and payment information are some of the most remarkable categories.  As an introduction, this 
text will not show a copy of each category of the database. Nevertheless, a copy of the NHIDB 
categories will be attached as an appendix.  
One of the strengths about using the NHIDB for the research is the sample size. It covers over 
99% of Taiwan’s 23million population. Furthermore, its extension permits studying the cost of 
each treatment in detail as well as controlling the prescript drugs.  Finally, as a patient is 
recorded with the same ID number, it is possible to study the clinical history and evolution. 
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As the NHIDB was designed as administrative data, there are some states where data is not 
enough clear for research or missing. Information about the health level of the patient, family 
history, exercise, diet or non-prescription drugs use is not included. That complicates researching 
and enforces to do some hypotheses and assumptions in order to continue the research in the 
most logical way. Every hypotheses and assumption will be explained with detail when 
necessary.  
CHAPTER 2: SEMI-MARKOV MODELLING 
2.1. Semi-Markov chain theory 
Mathematically, semi-Markov process is a stochastic process that assumes finite sets of a 
state during a continuous time T. An essential property that primes in the semi-Markov process is 
that the transition values depend on the time spent in the current state.  
During the research, the analysis performed was ruled by multi-state semi-Markov premises. The 
semi-Markov process is a particular case of ordinary Markov model in which the restrictive 
homogeneous transition probabilities of Markov property assumption are relaxed. From 1993 
with Sonnenberg and Beck it has been proved that semi-Markov model, in which the transition 
probabilities depend on the time that a patient has been on the current state, fits better in medical 
models than traditional Markov models.  
When it comes to the statistical distribution used, the Weibull distribution is the one chosen for 
modeling the waiting time in the current state.  
2.2. State definition 
Notation: The very first time that a disease appears in this inform its ICD9 code and 
abbreviation will be noted between parentheses for a precise identification.  
The main diseases that are going to be studied on this thesis are pulmonary Tuberculosis, 
primary lung cancer, Adrenal glands metastatic cancer, brain metastatic cancer, bone metastatic 
cancer and liver metastatic cancer. 
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2.3. Connections between diseases 
Figure 1 shows the possible states that will be taken in consideration in the study. Some 
transitions have been deleted to avoid useless data. For instance, obviously an AIDS patient can 
eventually die, but as long as that fact has no relation with the respiratory diseases or cancer 
varieties studied, will not be included in the study.  Similarly, it will be proceed with rheumatoid 
arthritis, diabetes and end stage renal disease. For all those, the study will only include their 
relation with pulmonary tuberculosis (the types of pulmonary tuberculosis will be explained in 
the next point).  
4
 
Figure 1: State diagram of the studied diseases 
Regarding pulmonary tuberculosis, the study will include its’ relation with the diseases named 
previously, with primary lung cancer, with health and death state as shown on the diagram.  
Referring to primary lung cancer, the study will include its’ relation with pulmonary 
tuberculosis, metastatic brain cancer, metastatic bone cancer, metastatic liver cancer, metastatic 
                                                 
4
Source: author 
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adrenal glands cancer, health and death. The first entries of the References show scientific 
articles that studied and proved the correlation between these diseases.  
Finally, the previously named metastatic cancers are connected with primary lung cancer, health 
and death, but the relationship between them will not be included in this study.  
2.4. Transient states 
Transient states are states in which by definition the patient will spend a finite time. There 
are some states that can possibly lead the patient to pulmonary TBC. As pulmonary TBC is an 
infectious disease caused by Mycobacterium tuberculosis or Mycobacterium bovis bacteria, 
immunosuppressive agents weakening our immunologic system will cause the infection. Agents 
under this study (stated as diseases) are*:  
When a visit is registered with one of the following codes shown between parentheses, it will be 
assumed that the patient is in the corresponding state. 
 AIDS (AIDS 042) 
 Rheumatoid arthritis (RA 714) 
 End stage renal disease (ESRD 585.6) 
 Diabetes mellitus (DM 250.X) 
*Drugs alcohol and tobacco and chemotherapy also weaken the immunologic system and can 
contribute to get infected with Tbc, but are not stated as diseases and we have no evidence of 
these factors in the NHIDB.  
Diabetes Mellitus state (DM) 
DM has different variants depending on the origin of the disease and the location that it affects. It 
will be assumed that the patient is in DM state when any of the following ICD9 codes are 
registered on the database.  
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Table 4: ICD9 codes for Diabetes Mellitus state 
ICD9 code Disease description 
250.0 Diabetes mellitus without mention of complication 
250.1 Diabetes with ketoacidosis 
250.2 Diabetes with hyperosmolarity 
250.3 Diabetes with other coma 
250.4 Diabetes with renal manifestations 
250.5 Diabetes with ophthalmic manifestations 
250.6 Diabetes with neurological manifestations 
250.7 Diabetes with peripheral circulatory disorders 
250.8 Diabetes with other specified manifestations 
250.9 Diabetes with unspecified complication 
5
 
Pulmonary tuberculosis state (TBC) 
TBC has different variants depending on the origin of the disease and the location that it affects. 
It will be assumed that the patient is in Pulmonary Tuberculosis state when any of the following 
ICD9 codes are registered on the database.  
Table 5: ICD9 codes for Pulmonary Tuberculosis state 
ICD9 code Disease description 
011.0 Tuberculosis of lung, infiltrative 
011.1 Tuberculosis of lung, nodular 
011.2 Tuberculosis of lung with cavitation 
011.3 Tuberculosis of bronchus 
011.4 Tuberculous fibrosis of lung 
011.5 Tuberculous bronchiectasis 
011.6 Tuberculous pneumonia 
011.7 Tuberculous pneumothorax 
011.8 Other specified pulmonary tuberculosis 
011.7 Tuberculous pneumothorax 
6
 
Primary lung cancer state (LC):  
LC is classified in ICD9 code depending on the origin, location and the kind of cancer cells. It 
will be assumed that the patient is in LC state when any of the following ICD9 codes are 
registered on the database: 
  
                                                 
5
Source: author 
6
Source: author 
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Table 6: ICD9 codes for Primary Lung Cancer State 
ICD9 code Disease description 
162.0 Trachea 
162.2 Main Bronchus 
162.3 Upper lobe, bronchus or lung 
162.4 Middle lobe, bronchus or lung 
162.5 Lower lobe, bronchus or lung 
162.8 Other parts of bronchus and lung 
162.9 Bronchus and lung, unspecified 
7
 
After suffering from LC, a patient can eventually heal, die or move to a metastatic state. In case 
of the latter, the patient will move to one of the next states: 
 Metastatic brain cancer (BRAINMET 198.3) 
 Metastatic bone cancer (BONEMET 198.5) 
 Metastatic liver cancer (LIVMET 197.7) 
 Metastatic adrenal glands cancer (ADREMET 198.7) 
2.5. Absorbing states 
Absorbing states are states in which by definition the patient will spend an infinite time. 
Every patient that heals but after some cycles relapses again into the disease will be treated by 
the model as a new patient. 
Death state 
No longer definition of death is needed because is an evident state. It will be assumed that a 
patient has the death status when there is evidence on the death status on columnTX_CODE 
category 08 (death status) or in column TRAN_CODE in categories 4 and A of the NHIDB of 
DD file. Nevertheless, owing to the high number of data missing, some hypothesis were 
necessary to be assumed in order to obtain a realistic number of transitions from LC and its 
metastatic states to heath and death states. 
 Hypothesis 1: due to the high deadly rate of cancer, it will be assumed that a patient that 
stayed more than 1 year with the illness will finally die from it. 
                                                 
7
Source: author 
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 Hypothesis 2: it will be assume that the date of the death is the date of the last medical 
visit recorded.  
Death state is defined as an absorbing state for obvious reasons. 
Health state  
It will be assumed that a patient has the health status (healthy patient that has overcome the 
disease) when the stay in the cancer states was no longer than 1 year. In order to complete the 
missing data, one hypothesis was assumed: 
 The patient left the country and no more data is recorded (available in column TX_CODE 
in category 04 of DD file shows if the patient left)is still alive.  
2.6. Monte Carlo simulation 
Monte Carlo simulation is a class of computer simulation classified as a fundamental 
numerical experimentation technique in probabilistic analysis. Monte Carlo simulation’s main 
aptitude is to translate sampled input statistics generating experimental trials into statistically 
computed output variables. Furthermore, Monte Carlo simulation is currently used to evaluate 
the long term effect of random variability of the input parameters on the outcomes. When it 
comes to decision analysis, the simulation is usually run to calculate an expected value for each 
decision path. Monte Carlo simulation effectiveness has been proven in the medical field in 
numerous models.  
Additionally, it was also proved that Monte Carlo simulation can be used to calculate an 
expected value over parameter uncertainty for particular strategy (decision analysis). 
Consequently, the simulation can also give an expected cost value which will be vital to the cost 
study.  
Finally, the Monte Carlo simulation can also be used to track the path (medical history) of every 
patient simulated. Due to all the features previously named, Monte Carlo simulation provides the 
characteristics needed for the study. 
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CHAPTER 3: MATERIALS AND MODEL DEVELOPMENT 
3.1. Data gathering process 
As said in the introduction, the data was obtained from the NHIDB. In section 2.3.2. ICD9 
codes are detailed for each one of the diseases studied. It is worth remembering that the codes 
detailed for metastatic cancers are different from the ones for primary cancers at the same 
locations, as ICD9 distinguish them.  
Firstly, using Microsoft SQL Server 2008, it was obtained from the database the patients that had 
the named diseases by pairs (see Figure 1). For instance, there was no interest in AIDS or TBC 
patients, but it was to do so with patients that suffered from AIDS and then TBC or first TBC 
and then LC respectively. Moreover, the initial and final dates of the disease were also obtained 
(first and last visit with the same ICD9 code), as well as the age, sex and other useful data.  
Secondly, the transition times were calculated following a simple process. Transition time was 
the time that a patient spent from the first visit for the first disease to the first visit of the second 
disease. The resultant time is the transition time between disease 1 and 2 (time infected with 
disease 1). As well as gathering the transition time, the total amount of the treatment was 
calculated for every patient in every state for further study.  
After proceeding similarly for all the possible pairs, those data was matched with the “Health and 
death data” to know which IDs eventually died. This data show which patients of the pair of 
diseases named previously died or are still alive. It is important to note that the quantity of data 
missing on the “Health and death data” was significantly large. To calculate the transition time to 
health or death states some hypotheses were necessary to assume.  
 Hypothesis 1: for the patients with the death status, it was assumed that the death date 
was the date of the last visit of the last disease of the pair. Transition time was calculated 
as the time that a patient spent from the first visit for the second disease to the last visit of 
the second disease. That is the time the patient spent infected with the second disease till 
death. 
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 Hypothesis 2: For patients with or without the live status, it was assumed that those that 
remained at the cancer for more than 1 year finally died of cancer at the date of their last 
visit. As explained in section 1.6.chances of healing from a long term cancer are very 
scarce. 
Finally, all the collected data was revised with the purpose that any impossible connections were 
introduced in the model, such as remaining in an illness and healing from a previous one for the 
same patient.  
3.2. Restrictions and limitations 
The data gathered was not enough for transitions 1 to 5, 4 to 5 and 7 to 10. Any of those 
connections had more than 10 patients. As the data gathered is data from real patients, and not 
enough to generate a general sample to solve this problem, states 1(AIDS), 4(ESRD) and 10 
(ADREMET) were deleted from the study.  
3.3. Final sample 
The final sample of population that satisfies all the features explained in the previous section 
is of 417 patients with a total of 773 inputs in the model. This number of patients may seem not 
enough compared to the current visits and patients stored in the NHIDB. Nonetheless, the cases 
studied –people with severe diseases and then Tuberculosis or with a metastatic cancer preceded 
by a primary lung one– are not really common. As the NHIDB is a database that stores real 
people medical data and is the only one available for the study, the final sample obtained shall be 
admitted as correct. 
3.4. Identification of Transition Probabilities 
The program used to calculate the transition probabilities between states was R for Statistical 
Computing x64 version 3.1.0 (R Core Team, 2014). Using the package Semi-Markov and 
programming a 9x9 transition matrix. The states involved were encoded from 1 to 9 as shown in 
table7. 
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Table7: Markov states classification and numbering 
State Code 
Rheumatoid arthritis 1 
Diabetes 2 
Pulmonary TBC 3 
LC 4 
Brain MET 5 
Bone MET 6 
Liver MET 7 
Death 8 
Health 9 
8
 
 
Semi-Markov states diagram
Rheumatoid 
arthritis
714
Pulmonary 
tuberculosis
011.X
Liver 
cancer
197.7
Bone 
cancer 
198.5
Brain 
cancer
198.3
Lung 
cancer
162.3-
162.9
Death
Health
Diabetes 
250.X
1
2
3 4
5
6
7
8
9
Figure 2: Semi-Markov states diagram 
Note the difference between Figure 1 and 2, when the second includes the possibility of 
remaining in the same state for one or more time steps. Furthermore, it does not include the 
deleted stage explained in section 3.2.  
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As regards the input data for R package to calculate the transition probabilities, the patients were 
stored in 4 columns, namely: ID code, state i (initial state), state j (final state) and transition time.  
Table8: Sample of input data format for R package 
ID code  State i State j Transition Time (months) 
1 4 6 0.76666667 
1 6 9 9.33333333 
2 3 4 0.6 
2 4 9 0.03333333 
3 4 7 27.2666667 
3 7 8 5.86666667 
4 1 3 14.6666667 
5 4 5 15.3 
5 5 8 0.03333333 
9
 
The next step to start the simulation was to determine the transition matrix. As explained 
previously, the essential property of the Semi-Markov process is that transition properties depend 
on the time spent in the current state.  
The model considered had a k state belonging to E = {1, 2,…,k} finite state space. Consider X0, 
X1, X2,…, Xn E be the successive states in N visits by a random process, in which 0 = T0< T1< 
… <Tnare the consecutive entrance times into each of these states. In the form of homogeneous 
Markov chain, the probabilities to move to state j from state i can be written as: 
Pij = P(Xn+1=j | Xn= i) (3.1) 
If state i is transient (not an absorbing state), then Pij≥ 0 for i≠j and Pij = 0 for i=j while Pij= 0 for 
i≠j and Pij= 1 for i=j if otherwise. However, it is obvious that the process does not deal with time 
issues. Hence, it is considered as semi-Markov process if the random process regards the 
transition sojourn time (Tn+1 – Tn) and its distribution satisfies: 
Qij(t)= P(Xn+1 = j, Tn+1 – Tn≤t | Xn= i) (3.2) 
The probability density function and the probability distribution function of the waiting time in 
state i before passing to state j is given by: 
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𝑓ij(t)= lim
∆t→0
P(t <Tn+1– Tn<t+∆t|Xn+1=j, Xn=i)
∆t
 
(3.3) 
Subsequently, we deduced from (3.3) the cumulative probability function, Fij(t) and the 
corresponding survival function of waiting time in state iSi.(t) as defined by: 
𝐹ij(t)=𝑃(𝑇𝑛+1 − 𝑇𝑛 ≤ 𝑡 |𝑋𝑛+1 = 𝑗, 𝑋𝑛 = 𝑖) =  
𝑄𝑖𝑗 (𝑡)
𝑃𝑖𝑗
 
(3.4) 
𝑆i.(t)= 1 − 𝑃(𝑇𝑛+1 −  𝑇𝑛 ≤ 𝑡 |𝑋𝑛 = 𝑖) =  ∑ 𝑃𝑖𝑗  (1 −  𝐹𝑖𝑗(𝑡))
𝑗∈𝐸
 
(3.5) 
Furthermore, we considered Weibull distributions to be used as the waiting time distribution. It 
generalizes exponential distribution by incorporating two parameters W(σij, vij),which is more 
flexible and well adapted to various shapes, especially when it was used in survival and medical 
studies. Therefore, following the application of Weibull distribution, instead of exponential 
distribution, the semi-Markov model is then generalized. The hazard function is defined by: 
𝛼ij(t)=𝑣𝑖𝑗 (
1
𝜎𝑖𝑗
)
𝑣𝑖𝑗
𝑡𝑣𝑖𝑗−1 , ∀ 𝑡 ≥ 0, ∀𝜎𝑖𝑗  ≥ 0, ∀𝑣𝑖𝑗  ≥ 0 
(3.6) 
Ultimately, the hazard function of the semi-Markov process, which represents the probability of 
transition towards state j between time t and t +∆t, given that the process is in state i for a 
duration t can be drawn. It follows: 
𝜆ij(t)= lim
∆t→0
P(Xn+1=j,t <Tn+1– Tn<t+∆t|Xn=i, Tn+1– Tn> t)
∆t
 
 
= 
𝑃𝑖𝑗𝑓𝑖𝑗(𝑡)
𝑆𝑖.(𝑡)
=  
𝑃𝑖𝑗𝑆𝑖𝑗(𝑡)𝛼𝑖𝑗(𝑡)
𝑆𝑖.(𝑡)
,      
𝑖, 𝑗 ∈ 𝐸
𝑖 ≠ 𝑗
 
(3.7) 
𝜆𝑖𝑖(t)= – ∑ 𝜆ij(𝑡)
𝑖≠𝑗
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The result from (3.7), can be interpreted as the subject’s risk of progressing from state i to state j 
after stayed in state i for t duration. Later on, those values were derivatively rooted to the 
simulation procedure as the input for the transition probability among Markov states. 
3.5. Cost parameters 
Due to the lack of detail on the data (as administrative, it showed the costs of drugs, 
treatment, diagnosis and lot more costs but not which treatment was applied), only the total cost 
will be taken in consideration. Those costs will be studied and compared to the simulation cost 
results for every disease.  
3.6. Simulation model structure 
The expected risk and survivability of the patient was analyzed through the semi-Markov 
model. This analysis was carried out by using Monte Carlo simulation procedure in TreeAge Pro 
2014 software, which presented the semi-Markov model in a probability tree structure as shown 
inFigure 3.For this simulation a hypothetical patient cohort of 50.000 patients was used. The 
study population from NHIRD served as the basis and source for input parameter data. 
The simulation model structure is explained as follows. An equal proportion of the virtual 
patients were set for each initial disease (encoded from 1 to 4, see Table4). The number of paths 
defined by the data gathering and the database characteristics is limited, as explained in section 
2.4. and 3.2. Two simulations will be run: one for the transient state (1 year horizon time) and 
one for the steady state (20 years horizon time).Bellow an illustration of de decision tree of the 
TreeAge program can be observed.   
 
  
24 
 
  
10
 
Figure 3: TreeAge decision tree  
                                                 
10
Source: TreeAge Pro 2014 
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Referring to the decision tree, a chance node is used to represent events that can possibly 
occur later for both paths. The chance to start the simulation in any of the first diseases (1 to 4) 
was the same for the steady state simulation, as a consequence of Markov theory (the transition 
probability only depends on the current state). Therefore, when the initial probabilities will not 
affect the simulation when the model is stabilized. Notwithstanding, for the transient state 
simulation, the initial probabilities were defined according to the real data because of its transient 
condition. 
The transition made by each patient, during each cycle, depends on the duration of stay in the 
current state. The transition risk to develop a metastasis is influenced by the time spent in 
primary lung cancer, as for the transition risk of being death depends on how long the patient has 
been in a primary or metastatic cancer. These time-dependent transition probabilities were 
obtained from the baseline semi-Markov process by using Equation 3.7. Furthermore, a set of 
Markov rewards were given to the patient during their stay in a particular state in each cycle. 
Each non-transient state has a different set of rewards. This set includes the survivability 
(lifetime) reward and cost reward. Both of them will be calculated and reported at the end of the 
simulation. In terms of costs, rewards were also differentiated y disease. Moreover, different 
tracker variables were defined to track additional information such as the duration of their lung 
cancer before the metastasis and the lifetime after developing metastasis.  
Referring to the cost trackers, the distribution that defined them was obtained using the Easyfit 
software on its 5.5 version. Then, the cost distributions were defined in the model for each 
disease so that the cost simulated was realistic.  
Additionally, half-cycle correction was applied to the simulation model in this study. The 
simulation was ruled by the assumption that in reality, transitions happen gradually in continuous 
during each cycle. By applying this correction, transitions are assumed to occur in half-way of a 
cycle, instead of simultaneously at the end of a cycle. 
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CHAPTER 4: SIMULATION AND RESULTS 
4.1. Monte Carlo simulation 
As explained in section2.6, the purpose of the simulation is to compute the baseline transition 
probability. The scenario used for the simulation is described as follows. A total of 50,000 
hypothetical patients were generated and simulated using the Monte Carlo simulation. The 
simulation time was 80 cycles for the steady state and 4 cycles for the transient state. The cycle 
length is 3 months. The steady state horizon time ensures a longer time than average lifetime 
cancer patients. By running the simulation using Monte Carlo method, each iteration shows each 
individual patient. The previously defined trackers allow us to obtain detailed information about 
each patient, such as the time spent and cost of every disease, the total lifetime and the diseases 
suffered.  
As simulating as explained in section 2.6, each iteration(patient)was randomly given one of the 
initial diseases at the beginning of the simulation. Hence, that starting state is recorded as 
patient’s first disease. In posterior cycles, the patient was able to either remain in that state or 
progress to a new state. Once a patient developed a metastatic cancer, will stay in their current 
state until died or healed. The simulation for that patient will stop when it reaches one of the 
following: the patient dies or is the end of simulation period. Following, a new simulation begins 
analogously for the next patient.  
The overall time spent in each disease, time spent in primary cancer, time spent in lung cancer 
until development of metastasis, survivability from metastatic cancers and total medical costs for 
every patient were estimated and evaluated through Monte Carlo simulation.   
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4.2. Results 
4.2.1. Baseline data 
As explained in section 3.3, the final sample contained 417 patients that were on 773 states. 
This number is the result of the sum of the total transitions performed by the real patients. An 
important percentage of them did more than one transition. The transition times (waiting time in 
the current disease till change to the next state) were calculated as detailed in section 3.4. Below, 
Table9 compiles the base proportion and profile of the studied population, as well as the average 
waiting time for every event experienced by patients.  
Table 9: Study population profile and proportion 
 Characteristics Number of patients Percentage (%) 
Age ≤50 years old 198 25.61% 
>50 years old 575 74.39% 
Gender Male 458 59.25% 
Female 315 40.75% 
 
Original state Final state Transition 
code 
Number of 
patients 
Percentage 
(%) 
Mean time 
(months) 
Rheumatoid arthritis Tuberculosis 13 16 2.08% 31.40625 
Diabetes Mellitus Tuberculosis 23 84 10.91% 33.98452381 
Tuberculosis Primary lung cancer 34 92 11.95% 53.91775362 
Death 38 22 2.86% 13.04393939 
Health 39 31 4.03% 2.163541667 
Primary lung cancer Tuberculosis 43 54 7.01% 12.78580247 
Metastatic brain cancer 45 66 8.57% 20.42424242 
Metastatic bone cancer 46 95 12.34% 12.75473684 
Metastatic liver cancer 47 29 3.77% 14.93563218 
Death 48 13 1.69% 52.94871795 
Health 49 79 10.26% 1.067088608 
Metastatic brain cancer 
(coming from lung) 
Death 58 46 5.97% 8.207246377 
Health 59 20 2.60% 2.906666667 
Metastatic bone cancer 
(coming from lung) 
Death 68 51 6.62% 11.86470588 
Health 69 43 5.58% 1.603875969 
Metastatic liver cancer 
(coming from lung) 
Death 78 13 1.69% 7.164102564 
Health 79 16 2.08% 3.09375 
11
 
As it can be observed, the population is mainly aged over 50 years old (74.39%). When it comes 
to the gender, the proportion is 59.25% men and 40.75% female patients, which is an acceptable 
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ratio for the study. Moreover, all of the patients of the study population have diagnosed one of 
the seven diseases of study (states 1 to 7). Referring to the proportion of patients in each 
transition, a significant difference between the number of patients in some states can be 
observed. As the study population was recorded from real patients, the sample was accepted. 
Regarding the transition times, transitions 34 and 48 are the ones with the biggest mean time 
between states. It is also remarkable that transitions that end at health state have significantly 
lower average times, as a consequence of the hypothesis assumed in the study (section 2.5). 
Bellow on Table10, are listed the average cost of treatment for each disease. It is worth to remark 
the difference in scale of the cost of the cancer diseases in front of the common diseases. For 
diseases 4 to 7 (primary and metastatic cancers) the cost is notably larger than for diseases 1 to 3. 
Especially for state 4, which average cost of treatment is about the triple of the average costs for 
metastatic cancer treatments in accordance with the length and material needed for these type of 
treatments.  
Table 10: Average cost of  treatment per patient for each disease 
State 1 2 3 4 5 6 7 
Average cost 
(NTD) 2,572.19 45,620.90 9,059.05 357,712.53 112,369.5 137,407.09 110,428.28 
12
 
4.2.2. Results from Semi-Markov modeling 
The analysis conducted while modeling the semi-Markov process was the calculation of the 
transition probabilities following the instructions detailed in section 3.4. As adopting the semi-
Markov bases for the model, the transition probability between states is time-dependent. Using 
the final sample explained in section 3.3 the time-dependent transition matrix was calculated 
using the baseline model of semi-Markov process, the transition probabilities were calculated 
using Equation 3.7. The transition probabilities obtained are only for transitions specified in 
Figure 2. From the resultant matrix it can be observed that most of the transition probabilities 
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follow a downward trend with longer duration in the current state. Real clinical experience with 
real patients shows that patients who experienced a recent alteration in their health state tend to 
have a short period of high instability after the transition. Nonetheless, when staying in a 
particular state for longer time, the disease stabilizes, which is reflected by a decrease in 
probability rates. Furthermore, extrapolation method was used to estimate the value of the 
probabilities out of the time horizon.  
Following, Figures 4, 5, 6 and 7 show the transition probabilities for some of the studied 
transitions depending on the time spent in the current state. These figures are a selection of the 
most representative transitions obtained. The rest of the graphics obtained are attached at the 
attachments.  
Figures4, 5, 6and 7: Transition probability for the specified transition vs. time.  
Figure 4: Transition probability vs. time for transitions 13 and 23 
13
 
This is the result obtained from the R package. As we can see, there is a final donward trend for 
Rheumatoid arthritis to Tuberculosis, as well as from Diabetes to Tuberculosis. A fact that can 
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explain the graph is that this two initial diseases are chronic diseases. Moreover, are not 
potentially deadly diseases so the popullation infected with them remains fairly stable within 
time.  
Figure 5: Transition probability vs. time for transitions 45, 46 and 47 
14
 
Figure5 shows the transition from primary lung cancer to metastatic brain bone and liver cancers 
respectively. As it can be appreciated, the graphs for the three transitions follow a similar trend. 
The patients who suffered a recent alteration in their health state are likely to have a short period 
of instability after it. However, as time passes, the health status stabilizes and the probability of 
transition is gradually reduced.  
Figure 6: Transition probability vs. time for transition 48 
15
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Figure 6shows the transition from primary lung cancer to death state. As supossed, patients 
infected with lung cancer have a little chance of being healed. As a deadly disease, the 
probabilities of overcoming the disease are reduced as time passes. This graph shows the rising 
trend of dying probability. However, as can be observed, from 90 months to the end of the period 
the probability decreases. There is no reasoning that can explain this trend. The data used to 
calculate this probabilities was from real patients but significantly incomplete and some 
assumptions were necessary to complete it, as explained in sections 3.1, 3.2 and 3.3. Obviously 
those assumptions have an influence on the times collected and may have influenced the results.  
 
Figure 7: Transition probability vs. time for transition 49 
16
 
This graph shows the probability of moving from state 4 (primary lung cancer) to state 9 
(health). As said previously, patients who suffered a recent alteration in their health status are 
likely to have a short period of instability after it. Moreover, as cancer tumors expand within 
time, the chances of healing from cancer are reduced when the tumor grows.  
4.2.3. Transient state simulation results 
Following the scenarios described in sections 3.6. and 4.1, the patients of the hypothetical 
cohort were simulated one by one through the model. For the transient state, the simulation time 
defined was of 1 year. Hence, the number of possible transitions, especially those towards health 
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and death, are greatly reduced within the overall simulation time.  Bellow, Table11 shows the 
number of patients and the percentage for each disease.  
Table 11: Number and percentage of patients infected with each disease in the transient simulation 
State RA DM TBC LC BRAINMET BONEMET LIVMET DEATH HEALTH 
Number of 
patients 1418 7177 13278 29376 231 372 104 112 284 
Percentage 
(%) 2.71% 13.71% 25.36% 56.11% 0.44% 0.71% 0.20% 0.21% 0.54% 
17
 
As can be observed, the proportion of patients that eventually develop a metastatic cancer is 
really low, as the cancer disease usually need more than one year time to evolve into a metastatic 
state. For the same reason, the number of dead patients simulated is very low even when 
developing a primary lung cancer. Furthermore, one year period is not enough time to heal from 
the studied diseases, which explains the low number of patients ending in the health state. 
Finally, it is remarkable that primary lung cancer contains the vast majority of the patients due to 
the initial probabilities given to the simulation, influenced by the real data, where primary lung 
cancer has a much more significant presence than the other initial diseases.  
To continue with the transient simulation results, Table12 shows the number of patients that 
performed each transition during the simulation. As explained before, the relative low number of 
transitions is a consequence of the short period of time simulated.  
Table12: Number of patients in each transition in the transient simulation  
Destination state 
Original  
state 
 
 
 
 
 
1 2 3 4 5 6 7 8 9 
1     39             
2     149             
3       1061       85 103 
4     2352   231 372 104 19 178 
5               2 0 
6               5 3 
7               1 0 
18
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As it can be observed, transitions 34 and 43 are the ones with the biggest amount of patients. 
Even so, the numbers are extremely small, which strengthens the argument of patients staying in 
the same state due to the short time horizon.  
Following, Table 13 shows the average time spent for each disease type during the transient 
simulation. It can be seen that the average time for initial diseases is close to 12 months, due to 
the short time available to develop another disease. Besides, the average time for the metastatic 
cancers is close to 7 months.  
Table 13: Average time spent in each disease during one year (months) 
Disease RA and Diabetes Primary lung cancer Metastatic Cancers Tuberculosis 
Time 11.89 11.58 6.80 11.52 
19
 
Finally, Table 14 shows the average cost of treatment for each disease per patient, during the 
period of one year.  
Table 14: Average treatment cost for each disease per patient during one year (NTD) 
  
Bone 
metastasis 
Brain 
metastasis  
RA and 
Diabetes 
Lung 
cancer  
Liver 
metastasis  
Tuberculosis 
 
Cost 275,126.89 234,901.72 114,969.27 504,384.69 331,117.94 30,117.66 
20
 
As regards to the average cost of treatment, it can be seen that primary lung cancer treatment is 
the most expensive treatment by far. The metastatic cancer treatments have similar costs among 
them, about 300,000.00 NTD. Thereafter, the common diseases treatment cost approximately 
115,000.00 NTD. Lastly, pulmonary tuberculosis has de cheapest treatment, about 
30,000.00NTD for a year of treatment.  
4.2.4. Steady state simulation results 
Following the scenarios described in sections 3.6. and 4.1, the patients of the hypothetical cohort 
were simulated one by one through the model. For the steady state, the simulation time defined 
was of 20 years.  
                                                 
19
Source: Author 
20
Source: Author 
  
34 
 
  
Table 15: Number and percentage of patients infected with each disease in the steady simulation 
Disease RA DM TBC LC BRAINMET BONEMET LIVMET DEATH HEALTH 
Number of 
patients 12266 12472 25753 19251 804 680 267 1059 347 
Percentage 
(%) 16.83% 17.11% 35.33% 26.41% 1.10% 0.93% 0.37% 1.45% 0.48% 
21
 
As it can be seen, the biggest percentage of patients occurred for pulmonary tuberculosis. As 
pulmonary tuberculosis is a pulmonary disease and its one of the initial diseases, it is consequent 
to the large number of patients being infected with it.  Rheumatoid arthritis, diabetes and lung 
cancer have also high percentage of patients. However, taking into account that the simulation 
time is 20 years, the metastatic cancers have surprisingly low number of patients being infected. 
Health and death states stand out for the same reason. This fact has an explanation. Using the 
time dependent probabilities for the simulation was not following strictly Markov laws. On 
chapter 5 (conclusions) further explanation can be found.  
Secondly, the transient simulation results about the number of patients that performed each 
transition during the simulation are shown in Table 16.  
Table 16: Number of patients in each transition in the steady simulation 
Destiny 
Origin 
 
 
 
 
 
 
1 2 3 4 5 6 7 8 9 
1     2882             
2     4259             
3       11872       483 180 
4     22899   804 680 267 460 163 
5               52 13 
6               38 5 
7               8 4 
22
 
Once again, the results are embarrassing. With the time horizon of 20 years, the number of 
transitions should be a lot bigger. Moreover, the number of transitions ending in the death state 
are a minority. Reminding that cancer is a deadly disease, it is shocking that lot of patients have 
lung cancer during 20 years without dying, healing or developing a metastasis. It is well known 
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for other researches that the long term survival rate for lung cancer patients is very low. As said 
before, on chapter five an explanation will be given for these results.  
To continue, Table 17 shows the average time spent for each disease type during the steady 
simulation. It can be seen that the average time for all the diseases is very high. It may be 
possible when talking about the common diseases (chronic diseases), but never possible when 
talking about primary lung cancer and metastatic cancers. These results are not realistic.  
Table 17: Average time spent in each disease during 20 years (months) 
Disease RA and Diabetes 
Primary lung 
cancer Metastatic cancers Tuberculosis 
Time 186.225867 147.521354 138.041475 160.119016 
23
 
Finally, Table 18 shows the average cost of treatment for each disease per patient, during the 
period of 20 years.  
Table 18: Average treatment cost for each disease per patient during 20 years (NTD) 
  
Bone 
metastasis 
Brain 
metastasis  
RA and 
Diabetes Lung cancer  
Liver 
metastasis  
Tuberculosis 
 
Cost 6,773,257.39 3,800,198.20 1,098,347.39 11,063,024.43 8,786,206.48 478,635.65 
24
 
Regarding the average cost of treatment, it can be seen that primary lung cancer treatment has 
once again the highest cost. Nevertheless, as happened with other steady results, stand out for its 
enormous magnitude. Such big costs are a consequence of the problem detected from Table 17. 
Is fairly known that cancer treatments are expensive. Combining this fact with the long time that 
patients remain in the model, it resulted in inflated costs.  
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CHAPTER 5: CONCLUSIONS 
5. Discussion and conclusions 
This study pretended to find the connection between common diseases, such as rheumatoid 
arthritis and diabetes, pulmonary diseases, such as pulmonary tuberculosis, and lung cancer and 
its most common metastatic cancers. A multi-state semi-Markov model has been implemented to 
model the patient’s health status using the real data from the National Health Insurance Data 
Base. Furthermore, the NHIDB provided the information to calculate the real transition times 
and basic costs. It is vital to say that the results from this first part of the study are greatly 
influenced by the hypothesis assumed in order to complete vital missing data (death status). 
Moreover, the cancer database couldn’t be used because other diseases (non cancer ones) were in 
the model. This fact caused that the final sample of cancer patients was smaller. Despite this fact, 
it was possible to build the model and run a simulation afterwards, as the robustness of a semi-
Markov model combined with a simulation method has been widely proved.   
The baseline data results accomplish one of the first objectives showing the total cost of 
treatment for each disease per patient in Table10. Note that the table shows the total cost for the 
entire period of disease. Furthermore, Figures 4, 5, 6 and 7 show the time dependent probabilities 
between states, which also provides an insight of the relationship between the diseases studied.  
When talking about the first simulation, it was run for a time horizon of 1 year to study the 
transient state. Results for this simulation are explained in section 4.2.3. This results show a very 
low percentage of infected patients dying. Even though it is the first year of the disease, the 
number of dead people simulated should be a lot bigger. This fact can be seen when comparing 
the simulation results from Table11 with the data extracted from scientific paper shown in Table 
3. When revising the process, it was found that the simulation and previous calculation were 
properly done. Nonetheless, two possible sources of error were found: 
 The first of them, as explained before, was the data used. The hypothesis used to complete the 
data were the best possible after trying several criteria, but it may not suit entirely to the reality.  
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The second source of error was the time dependent method used. Using a time dependent 
transition probability matrix for the simulation was not following strictly Markov laws. The 
proper way to do it should be a two-step Markov process: firstly, with the fixed probabilities 
decide which the next state was. Secondly, calculate the time. However, based on previous thesis 
and the available methods, it was decided to use this adapted method at the beginning of the 
study. 
Referring to the cost study results from the transient simulation, it is necessary to say that were 
calculated from distributions obtained from the real data. Despite results on Table 11 only shows 
the yearly total cost of treatment and the study does not include a segmented cost study 
depending on the treatment, the results give a basic insight of the total amount to spend in each 
patient.  
Regarding the steady state simulation, results were far from expected. The methodological 
error explained in the previous paragraphs was magnified when extending the time horizon to 
20 years. The low time dependent probabilities made patients remain in the model for an 
outrageously high time, and this fact distorted all the results.  
In a future study, should be taken in consideration that long term simulation cannot be run 
using time dependent transition probabilities in such a big model (nine states) because 
simulated patients tend to remain in the model.  
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Copy of the categories of the NHIDB 
 
